During the recent session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 0.55 million, with the beta value of the company hitting 2.49. At the last check today, the stock’s price was $5.80, reflecting an intraday loss of -5.16% or -$0.31. The 52-week high for the BDTX share is $7.66, that puts it down -32.07 from that peak though still a striking 72.07% gain since the share price plummeted to a 52-week low of $1.62. The company’s market capitalization is $327.42M, and the average intraday trading volume over the past 10 days was 0.62 million shares, and the average trade volume was 629.70K shares over the past three months.
Black Diamond Therapeutics Inc (BDTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.17. BDTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.35.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Black Diamond Therapeutics Inc (BDTX) registered a -5.16% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.16% in intraday trading to $5.80, hitting a weekly high. The stock’s 5-day price performance is -10.29%, and it has moved by -4.37% in 30 days. Based on these gigs, the overall price performance for the year is 66.52%. The short interest in Black Diamond Therapeutics Inc (NASDAQ:BDTX) is 6.01 million shares and it means that shorts have 13.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $14, which implies an increase of 58.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11 and $20 respectively. As a result, BDTX is trading at a discount of -244.83% off the target high and -89.66% off the low.
Black Diamond Therapeutics Inc (BDTX) estimates and forecasts
Statistics show that Black Diamond Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Black Diamond Therapeutics Inc (BDTX) shares have gone up 21.23% during the last six months, with a year-to-date growth rate more than the industry average at 24.47% against 20.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -49.79%. While earnings are projected to return 24.47% in 2024.
BDTX Dividends
Black Diamond Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
Black Diamond Therapeutics Inc insiders own 2.33% of total outstanding shares while institutional holders control 95.22%, with the float percentage being 97.48%. T. ROWE PRICE INVESTMENT MANAGEMENT, INC. is the largest shareholder of the company, while 118.0 institutions own stock in it. As of 2024-06-30, the company held over 10.66 million shares (or 20.5751% of all shares), a total value of $49.67 million in shares.
The next largest institutional holding, with 8.52 million shares, is of BELLEVUE GROUP AG’s that is approximately 16.4409% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $39.69 million.
